Notice of the Annual General Meeting of Vitrolife AB (publ)
1 april, 18:00
Notice of the Annual General Meeting of Vitrolife AB (publ)
The Annual General Meeting of Vitrolife AB (publ), 556354–3452, will be held on Tuesday 5 May 2026 at 17:00 CEST at Elite Park Avenue Hotel, Kungsportsavenyn 36-38 in Gothenburg, Sweden. Registration for the Annual General Meeting will commence at 16:30 CEST. The Board has decided that shareholders may exercise their voting rights at the Annual General Meeting also by postal voting in advance, in accordance with the provisions of the Articles of Association.
The notice is attached to this press release, and is also available at the company's website, www.vitrolifegroup.com.
PARTICIPATION
Shareholders who wish to participate in the Annual General Meeting must be recorded as a shareholder in the presentation of the share register prepared by Euroclear Sweden AB concerning the circumstances on Friday 24 April 2026; and give notice of participation no later than Tuesday 28 April 2026.
To be entitled to participate in the Annual General Meeting, shareholders whose shares are registered in the names of nominees must, in addition to giving notice of participation in accordance with the instructions below, register such shares in their own name so that the shareholder is recorded in the presentation of the share register as of Friday 24 April 2026. Such registration may be temporary (so called voting rights registration) and can be requested from the nominee in accordance with the nominee's procedures in such time in advance as the nominee determines. Voting rights registrations effected by the nominee no later than Tuesday 28 April 2026 will be considered in the presentation of the share register.
Participation at the meeting venue
Shareholders who wish to attend the meeting venue in person or by proxy must give notice of participation no later than Tuesday 28 April 2026 via Euroclear Sweden AB's website at www.euroclear.com/sweden/generalmeetings/, by telephone to +46 (0) 8 402 58 74, or by post to Vitrolife AB (publ), "AGM", c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden. Shareholders shall in their notice of participation state their name, personal identification number or company registration number, address and phone number. If the shareholder is represented by a proxy, a written and dated power of attorney signed by the shareholder shall be issued to the proxy. A template proxy form is available on the company's website at www.vitrolifegroup.com. If the shareholder is a legal entity, a registration certificate or a corresponding authorisation document shall be enclosed. To facilitate registration at the Annual General Meeting, the power of attorney, registration certificate and other authorisation documents should be sent to the company at the above address well in advance of the Annual General Meeting.
Participation by postal voting
Shareholders who wish to participate in the Annual General Meeting by postal voting must give notice of participation by casting their postal vote so that it is received by Euroclear Sweden AB no later than Tuesday 28 April 2026. A special form shall be used for postal voting. The postal voting form is available on the company's website at www.vitrolifegroup.com. The postal voting form can be submitted either by email to GeneralMeetingService@euroclear.com, or by post to Vitrolife AB (publ), "AGM", c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden. Shareholders may also cast their postal votes electronically through verification with BankID via Euroclear Sweden AB's website at www.euroclear.com/sweden/generalmeetings/. If the shareholder postal votes by proxy, a written and dated power of attorney signed by the shareholder shall be enclosed with the form. A template proxy form is available on the company's website at www.vitrolifegroup.com. If the shareholder is a legal entity, a registration certificate or a corresponding authorisation document shall be enclosed with the form. Further instructions can be found on the postal voting form and on Euroclear Sweden AB's website at www.euroclear.com/sweden/generalmeetings/.
PROPOSED AGENDA
- Opening of the Annual General Meeting.
- Election of Chairman of the Annual General Meeting.
- Preparation and approval of the voting list.
- Approval of the agenda.
- Election of one or two persons to check and verify the minutes.
- Determination of whether the Annual General Meeting has been duly convened.
- Presentation by the Chief Executive Officer.
- Presentation of the Annual Report and the Auditor's report as well as the Consolidated Accounts and the Group Audit Report.
- Resolution on:
- adoption of the Income Statement and Balance Sheet as well as the Consolidated Income Statement and Consolidated Balance Sheet;
- disposition of the company's profits in accordance with the adopted Balance Sheet and determination of record the date for dividend; and
- discharge from liability for the Board members and the Chief Executive Officer.
- Presentation and resolution on approval of the Board's Remuneration Report.
- Report on the work and proposals of the Nomination Committee.
- Determination of the number of Board members and the number of Auditors and any Deputy Auditors.
- Determination of the remuneration to the Board members and Auditors.
- Election of Board members and the Chairman of the Board as well as Auditors and any Deputy Auditors.
Board members:
- Henrik Blomquist (re-election);
- Karen Lykke Sørensen (re-election);
- Pia Marions (re-election);
- Jón Sigurdsson (re-election);
- Nicklas Hansen (new election); and
- David T. Hansen (new election).
Chairman of the Board:
- Jón Sigurdsson (re-election).
Auditor:
- Deloitte AB (re-election).
- Approval of the procedure of the Nomination Committee.
- Resolutions regarding a long-term share incentive plan for 2026:
- adoption of the plan; and
- issue of warrants and transfer of warrants to the participants or a third party; or
- share swap agreement with a third party in relation to the plan.
- Resolution on authorisation for the Board to resolve to issue shares.
- Resolution on authorisation for the Board to resolve on acquisitions of own shares.
- Resolution on amendments to the Articles of Association.
- Closing of the Annual General Meeting.
The information was submitted for publication, through the agency of the contact persons set out above, at 01-04-2026 18:00 CET.
Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,150 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.
Contact:
Jón Sigurdsson, chairman of the Board,
email: jon@emblamedical.com
Pär Ihrskog, CFO
email: pihrskog@vitrolifegroup.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Ämnen i artikeln
Notice of the Annual General Meeting of Vitrolife AB (publ)
1 april, 18:00
Notice of the Annual General Meeting of Vitrolife AB (publ)
The Annual General Meeting of Vitrolife AB (publ), 556354–3452, will be held on Tuesday 5 May 2026 at 17:00 CEST at Elite Park Avenue Hotel, Kungsportsavenyn 36-38 in Gothenburg, Sweden. Registration for the Annual General Meeting will commence at 16:30 CEST. The Board has decided that shareholders may exercise their voting rights at the Annual General Meeting also by postal voting in advance, in accordance with the provisions of the Articles of Association.
The notice is attached to this press release, and is also available at the company's website, www.vitrolifegroup.com.
PARTICIPATION
Shareholders who wish to participate in the Annual General Meeting must be recorded as a shareholder in the presentation of the share register prepared by Euroclear Sweden AB concerning the circumstances on Friday 24 April 2026; and give notice of participation no later than Tuesday 28 April 2026.
To be entitled to participate in the Annual General Meeting, shareholders whose shares are registered in the names of nominees must, in addition to giving notice of participation in accordance with the instructions below, register such shares in their own name so that the shareholder is recorded in the presentation of the share register as of Friday 24 April 2026. Such registration may be temporary (so called voting rights registration) and can be requested from the nominee in accordance with the nominee's procedures in such time in advance as the nominee determines. Voting rights registrations effected by the nominee no later than Tuesday 28 April 2026 will be considered in the presentation of the share register.
Participation at the meeting venue
Shareholders who wish to attend the meeting venue in person or by proxy must give notice of participation no later than Tuesday 28 April 2026 via Euroclear Sweden AB's website at www.euroclear.com/sweden/generalmeetings/, by telephone to +46 (0) 8 402 58 74, or by post to Vitrolife AB (publ), "AGM", c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden. Shareholders shall in their notice of participation state their name, personal identification number or company registration number, address and phone number. If the shareholder is represented by a proxy, a written and dated power of attorney signed by the shareholder shall be issued to the proxy. A template proxy form is available on the company's website at www.vitrolifegroup.com. If the shareholder is a legal entity, a registration certificate or a corresponding authorisation document shall be enclosed. To facilitate registration at the Annual General Meeting, the power of attorney, registration certificate and other authorisation documents should be sent to the company at the above address well in advance of the Annual General Meeting.
Participation by postal voting
Shareholders who wish to participate in the Annual General Meeting by postal voting must give notice of participation by casting their postal vote so that it is received by Euroclear Sweden AB no later than Tuesday 28 April 2026. A special form shall be used for postal voting. The postal voting form is available on the company's website at www.vitrolifegroup.com. The postal voting form can be submitted either by email to GeneralMeetingService@euroclear.com, or by post to Vitrolife AB (publ), "AGM", c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden. Shareholders may also cast their postal votes electronically through verification with BankID via Euroclear Sweden AB's website at www.euroclear.com/sweden/generalmeetings/. If the shareholder postal votes by proxy, a written and dated power of attorney signed by the shareholder shall be enclosed with the form. A template proxy form is available on the company's website at www.vitrolifegroup.com. If the shareholder is a legal entity, a registration certificate or a corresponding authorisation document shall be enclosed with the form. Further instructions can be found on the postal voting form and on Euroclear Sweden AB's website at www.euroclear.com/sweden/generalmeetings/.
PROPOSED AGENDA
- Opening of the Annual General Meeting.
- Election of Chairman of the Annual General Meeting.
- Preparation and approval of the voting list.
- Approval of the agenda.
- Election of one or two persons to check and verify the minutes.
- Determination of whether the Annual General Meeting has been duly convened.
- Presentation by the Chief Executive Officer.
- Presentation of the Annual Report and the Auditor's report as well as the Consolidated Accounts and the Group Audit Report.
- Resolution on:
- adoption of the Income Statement and Balance Sheet as well as the Consolidated Income Statement and Consolidated Balance Sheet;
- disposition of the company's profits in accordance with the adopted Balance Sheet and determination of record the date for dividend; and
- discharge from liability for the Board members and the Chief Executive Officer.
- Presentation and resolution on approval of the Board's Remuneration Report.
- Report on the work and proposals of the Nomination Committee.
- Determination of the number of Board members and the number of Auditors and any Deputy Auditors.
- Determination of the remuneration to the Board members and Auditors.
- Election of Board members and the Chairman of the Board as well as Auditors and any Deputy Auditors.
Board members:
- Henrik Blomquist (re-election);
- Karen Lykke Sørensen (re-election);
- Pia Marions (re-election);
- Jón Sigurdsson (re-election);
- Nicklas Hansen (new election); and
- David T. Hansen (new election).
Chairman of the Board:
- Jón Sigurdsson (re-election).
Auditor:
- Deloitte AB (re-election).
- Approval of the procedure of the Nomination Committee.
- Resolutions regarding a long-term share incentive plan for 2026:
- adoption of the plan; and
- issue of warrants and transfer of warrants to the participants or a third party; or
- share swap agreement with a third party in relation to the plan.
- Resolution on authorisation for the Board to resolve to issue shares.
- Resolution on authorisation for the Board to resolve on acquisitions of own shares.
- Resolution on amendments to the Articles of Association.
- Closing of the Annual General Meeting.
The information was submitted for publication, through the agency of the contact persons set out above, at 01-04-2026 18:00 CET.
Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,150 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.
Contact:
Jón Sigurdsson, chairman of the Board,
email: jon@emblamedical.com
Pär Ihrskog, CFO
email: pihrskog@vitrolifegroup.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Ämnen i artikeln
Analys
Rapporter
Lyxsektorn
Svensk ekonomi
Analys
Rapporter
Lyxsektorn
Svensk ekonomi
Marknadsöversikt
1 DAG %
Senast
1 mån
